Skip to main content
. 2023 Oct 5;23:941. doi: 10.1186/s12885-023-11435-8

Table 1.

Relationships between Modified Naples prognostic score and clinicopathological characteristics

Modified Naples prognostic score
Variables Total Group 0 Group 1 Group 2 P*
Age(yr) 65(55–71) 63 (54–67) 65(55–71) 71(64–79) 0.005
Sex 0.010
Male 102(52.0) 21(36.8) 61(55.5) 20(69.0)
Female 94(48.0) 36(63.2) 49(44.5) 9(31.0)
BMI (mean ± SD) 22.1 ± 2.8 21.9 ± 2.7 22.2 ± 2.7 22.0 ± 3.2 0.768
ASA class 0.011
1 5(2.5) 2(3.5) 3(2.7) 0(0.0)
2 126(64.3) 42(73.7) 68(61.8) 16(55.2)
3 35(17.9) 10(17.5) 19(17.3) 6(20.7)
4 30(15.3) 3(5.3) 20(18.2) 7(24.1)
1/2 131(66.8) 44(77.2) 71(64.5) 16(55.2) 0.090
3/4 65(33.2) 13(22.8) 39(35.5) 13(44.8)
Location 0.214
Right colon 63(32.1) 19(33.3) 38(34.5) 6(20.7)
Left colon 78(39.8) 19(33.3) 42(38.2) 17(58.6)
Rectum 55(28.1) 19(33.3) 30(27.3) 6(20.7)
Size (cm) 0.047
d<5 97(49.5) 36(63.2) 49(44.5) 12(41.4)
d ≥ 5 99(50.5) 21(36.8) 61(55.5) 17(58.6)
Differentiation 0.487
Low 28(14.3) 5(8.8) 18(16.4) 5(17.2)
Medium 136(69.4) 43(75.4) 74(67.3) 19(65.5)
High 32(16.3) 9(15.8) 18(16.4) 5(17.2)
TNM stage
I 5(2.5) 1(1.8) 4(3.6) 0(0.0) 0.745
II 85(43.4) 26(45.6) 46(41.8) 13(44.8)
III 94(48.0) 27(47.4) 53(48.2) 14(48.3)
IV 12(6.1) 3(5.3) 7(6.4) 2(6.9)
I/II 90(45.9) 27(47.4) 50(44.5) 13(44.8) 0.965
III/IV 106(54.1) 30(52.6) 60(55.5) 16(55.2)
Tumor
T1 6(3.1) 0(0.0) 6(5.5) 0(0.0) 0.237
T2 23(11.7) 5(8.8) 11(10.0) 7(24.1)
T3 89(45.4) 30(52.6) 45(40.9) 14(48.3)
T4 78(39.8) 22(38.6) 48(43.6) 8(27.6)
T1/2 29(14.8) 5(8.8) 17(15.5) 7(24.1) 0.158
T3/4 167(85.2) 52(91.2) 93(84.5) 22(75.9)
Node 0.675
N0 96(49.0) 27(47.4) 55(50.0) 14(48.3)
N1 68(34.7) 18(31.6) 40(36.4) 10(34.5)
N2 32(16.3) 12(21.1) 15(13.6) 5(17.2)
N0a 96(49.0) 27(47.4) 55(50.0) 14(48.3) 0.946
N1/2 100(51.0) 30(52.6) 55(50.0) 15(51.7)
Metastasis 1.000
M0 191(97.4) 56(98.2) 107(97.3) 28(96.6)
M1 5(2.6) 1(1.8) 3(2.7) 1(3.4)
Vascular Tumor Thrombus 0.195
No 150(76.5) 39(68.4) 89(80.9) 22(75.9)
Yes 46(23.5) 18(31.6) 21(19.1) 7(24.1)
Nerve Invasion 0.453
No 137(69.9) 40(70.2) 74(67.3) 23(79.3)
Yes 59(30.1) 17(29.8) 36(32.7) 6(20.7)
LNR (%) 2.6(0.0-14.4) 3.3(0.0-17.6) 0.0(0.0-14.2) 3.1(0.0-12.5) 0.786
SEMS implantation 0.068
No 155(79.1) 51(89.5) 83(75.5) 21(72.4)
Yes 41(20.9) 6(10.5) 27(24.5) 8(27.6)
Chemotherapy 0.303
No 110(56.1) 28(49.1) 67(60.9) 15(51.7)
Yes 86(43.9) 29(50.9) 43(39.1) 14(48.3)
Radiotherapy 0.353
No 190(96.9) 56(98.2) 107(97.3) 27(93.1)
Yes 6(3.1) 1(1.8) 3(2.7) 2(6.9)
CEA (ng/ml) 5.7(2.7–16.4) 5.1(2.4–12.4) 6.7(2.9–20.6) 5.5(3.5–17.6) 0.364
NPS factors
ALB (g/L) 38.1(34.7–40.3) 39.8(38.3–42.6) 37.8(34.2–40.3) 33.6(31.3–35.9) < 0.001
CHOL (mmol/L) 4.3(3.6–4.8) 4.4(4.3–4.8) 4.3(3.6-5.0) 3.0(2.6–3.3) < 0.001
NLR 3.1(2.0-5.2) 2.0(1.6–2.5) 3.6(2.4–5.3) 6.2(4.3–13.6) < 0.001
LMR 2.9(2.0–4.0) 4.4(3.6-5.0) 2.6(2.0-3.3) 1.8(1.3–2.2) < 0.001

ASA class adopted binary classification (1/2 vs. 3/4)

TNM stage adopted binary classification (I/II vs. III/IV).

Tumor stage adopted binary classification (T1/2 vs. T3/4)

Node stage adopted binary classification (N0 vs. N1/2)

Right colon: the proximal two-thirds of the transverse colon, ascending colon and caecum

left colon: the distal third of the transverse colon, splenic flexure, descending colon, sigmoid colon

*P was calculated by the Kruskal–Wallis tests and the analysis of variance (ANOVA) for continuous variables and the Chi-square test and the Spearman’s rank correlation test for categorical variables